Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 235 results

Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

PAR
Wednesday, October 13, 2021
Saturday, March 12, 2022
R01
PAR-22-048

Funding Opportunity Purpose

There is consensus that environmental toxicants are a risk factor for AD/ADRD, but causality has been largely elusive. While human studies demonstrating an association of AD/ADRD with toxicant exposures are relatively abundant, there is a clear unmet need for more mechanistic research to support or refute the clinical relevance and the biological plausibility of an impact on disease initiation, progression, or modification. This is especially important for understanding the potentially modifiable causes of racial and socioeconomic inequities. The RFA will encourage neuroscientists to conduct mechanistic AD/ADRD research on the actions of neurotoxicants on the nervous system. The scope of research includes but is not limited to in silico modeling, in vitro assay development to correlate chemical exposure to AD/ADRD biology, and in vivo studies on the modification of known AD/ADRD targets by neurotoxicants of concern, and conversely, whether known targets for these neurotoxins play a role in the etiology of AD/ADRD. The development and validation of neuropathological, neurophysiological, and neurobehavioral animal models that simulate potential toxicant exposures in humans would be one goal, and when possible, these studies will include comparisons of exposures across the lifespan.

Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimer’s Disease and Related Dementias (R01 Clinical Trial Not Allowed)

PAR
Wednesday, October 13, 2021
Neural Exposome, ONETOX
Saturday, March 12, 2022
R01
PAR-22-048
David A. Jett

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) supports mechanistic and early translational research focused on a more rigorous in-depth examination of the potential interactions of environmental toxins with genetic and non-genetic molecular targets known to influence Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). It is expected that these studies will address the clinical relevance of these exposures on disease initiation, progression, or modification. Anticipated outcomes include an improved understanding of neurological mechanisms of chemical toxicities related to AD/ADRD, more evidence-based potential biomarkers of exposure and toxicity for those most at risk, as well as more data to support causality and potential approaches for mitigation. The scope of research includes mechanistic studies on the modification of known AD/ADRD targets by neurotoxins of concern, and conversely, whether known targets for these neurotoxins play a role in etiologies of AD/ADRD. The development and validation of neuropathological, neurophysiological and neurobehavioral animal models that simulate potential toxin exposures in humans is another example of supported studies. Preclinical studies of interactions of environmental toxicant with AD/ADRD in pilot human subject studies (that do not meet the NIH definition of clinical trial) are appropriate for this FOA. Interdisciplinary collaboration is required to address the various fields of study related to this research, e.g., neuroscience, aging, and environmental health sciences.

HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required)

RFA
Friday, October 8, 2021
Friday, December 10, 2021
R61/R33
RFA-NS-22-002

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to accelerate development, testing and implementation of evidence-based interventionsthat are culturally and linguistically appropriate for NIH-designated health disparity populations[1] (HDPs)to mitigate disparities in provision of care and treatment decisions, reduce susceptibility to chronic pain and improve patient outcomes. Applications are encouraged for studies that utilize evidence-based strategies that mitigate: 1) the effects of bias, stigma and discrimination at multiple levels, and 2) socioeconomic, environmental and other barriers to quality pain assessment, treatment and management are desired outcomes of this initiative. Strategies to increase successful HDP patient engagement and bolster inclusion to enhance better pain management outcomes are also desired.

Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)

PAR
Tuesday, October 5, 2021
Neural Exposome, ONETOX
Saturday, June 22, 2024
R01
PAR-21-349
David A. Jett

Funding Opportunity Purpose

This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. NIH considers such studies as Basic Experimental Studies with Humans (BESH) that are prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024). Applications should not propose a goal of clinical outcomes or products. Applications that propose studies including model animal research or observational studies involving humans should submit under the companion FOA, PAR-21-350 "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed).

Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)

PAR
Tuesday, October 5, 2021
ONETOX
Saturday, June 22, 2024
R01
PAR-21-349
David A. Jett

Funding Opportunity Purpose

This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolatedness. NIH considers such studies as prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of clinical trials (see, e.g., NOT-OD-19-024) Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applications proposing studies that include but not limited to model animal research or observational studies involving humans should submit under the companion Clinical Trials Not Allowed version of this FOA.

Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)

PAR
Tuesday, October 5, 2021
Neural Exposome, ONETOX
Saturday, June 22, 2024
R01
PAR-21-350
David A. Jett

Funding Opportunity Purpose

This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed. Researchers proposing Basic Experimental Studies with Humans (BESH) should consider the companion FOA, PAR-21-349, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)".

Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)

PAR
Tuesday, October 5, 2021
ONETOX
Saturday, June 22, 2024
R01
PAR-21-350
David A. Jett

Funding Opportunity Purpose

This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider the companion FOA TEMP-14931 "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)".

Neurosurgeon Research Career Development Program (NRCDP) (K12 Independent Clinical Trial Not Allowed)

RFA
Monday, October 4, 2021
Thursday, December 16, 2021
K12
RFA-NS-21-019

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to invite applications to continue support of a national program of mentored research career development for junior neurosurgeon faculty at institutions nationwide that support neurosurgical research. The goal of the program is to expand the cadre of neurosurgeon investigators trained to conduct research into neurological disorders, making use of their neurosurgical training.

Notice of Special Interest: Biomarker Discover and Validation in Functional Neurological Disorders

Notice of Special Interest
Friday, October 1, 2021
Wednesday, January 8, 2025
NOT-NS-22-010

Funding Opportunity Purpose

NINDS is issuing this Notice of Special Interest to encourage the submission of applications focused on the development and validation of biomarkers for functional neurological disorders (FND). FND are a complex and heterogeneous group of neuropsychiatric syndromes. They are characterized by symptoms of altered voluntary motor or sensory function and frequently have comorbid medical, neurological, and psychiatric disorders. Although patients with FND represent the second commonest category of referrals to neurology outpatient clinics after headache, management is complex and requires interdisciplinary approaches. The high prevalence of FND, the disability caused by symptoms, high cost in healthcare utilization and loss of productivity points to an important opportunity for development of effective therapeutic interventions. This common, disabling, and costly group of conditions sits at the intersection of neurology and psychiatry. In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) the term functional is used as the primary descriptor in the term for this group of conditions, although the term conversion disorder is still accepted as an alternative expression that acknowledges unconscious processes in patients, though it emphasizes the implicit inference of causative psychological stressors, which are not always present or may not be readily identifiable. Diagnostic criteria for FND have been proposed, but are not universally accepted, and have varying rates of interrater reliability, depending on the symptom presentation (high for non-epileptic psychogenic seizures; poor for other FND). For this reason, diagnosis remains very challenging. Recent recommendations suggest that diagnosis should be based on positive clinical findings and supported, when necessary, by laboratory or ancillary investigation findings. Certain FND subtypes are more difficult to correctly diagnose than others.

Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed)

PAR
Thursday, September 30, 2021
Saturday, February 5, 2022
R01
PAR-22-037

Funding Opportunity Purpose

The neurovascular unit involves multiple pathways that contribute to neurodegeneration. Astrocytes, due to their overlapping roles regulating the blood brain barrier, neuronal health and response to degenerating cells, are uniquely positioned to be therapeutic targets. Astrocytes are a fundamental component of the neurovascular unit and are known to play a role in regulating the blood brain barrier and APOE signaling. However, the mechanistic role of astrocytes for the neurovascular unit in health and disease, including in vascular contributions to cognitive impairment and dementia (VCID) and across the spectrum of AD/ADRD diagnoses, is largely unknown, and represents a gap area and an opportunity for research investment. This initiative would represent the first targeted initiative on the fundamental role of astrocytes in AD/ADRD at the NIH.

Pages